Insmed (INSM) is a biopharmaceutical company with strong momentum. Shares are trading at new 20-year highs. INSM has surged 128% over the past year. Analysts expect robust revenue and earnings growth, but opinions are mixed, with some cautioning the stock is overvalued. Today’s Featured Stock Valued at $34.3 billion, Insmed (INSM) is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, a treatment for rare lung conditions. Insmed is also focused on the devel ...